![Merck's KEYTRUDA ® (pembrolizumab) Approved in Japan for three additional first-line indications around RCC and chronic or remote metastatic head and neck cancer – Medical Herald Merck's KEYTRUDA ® (pembrolizumab) Approved in Japan for three additional first-line indications around RCC and chronic or remote metastatic head and neck cancer – Medical Herald](https://medgazette24.com/wp-content/uploads/2019/12/Mercks-KEYTRUDA-%C2%AE-pembrolizumab-Approved-in-Japan-for-three-additional-first-line-indications-around-RCC-and-chronic-or-remote-metastatic-head-and-neck-cancer-1024x576.jpg)
Merck's KEYTRUDA ® (pembrolizumab) Approved in Japan for three additional first-line indications around RCC and chronic or remote metastatic head and neck cancer – Medical Herald
![KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) - Scipreneur KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) - Scipreneur](https://secureservercdn.net/50.62.172.157/f73.32e.myftpupload.com/wp-content/uploads/2016/12/merck-co-inc-keytruda-granted-priority-review-for-treating-lung-cancer-678x381.jpg)
KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) - Scipreneur
![Keytruda Pembrolizumab Injection, Treatment: Melanoma, Dose Strength: 100 Mg / 4 mL (25 Mg/ml), Rs 132000 /bottle | ID: 21366458612 Keytruda Pembrolizumab Injection, Treatment: Melanoma, Dose Strength: 100 Mg / 4 mL (25 Mg/ml), Rs 132000 /bottle | ID: 21366458612](https://5.imimg.com/data5/NC/ZQ/XH/ANDROID-89072554/product-jpeg-500x500.png)
Keytruda Pembrolizumab Injection, Treatment: Melanoma, Dose Strength: 100 Mg / 4 mL (25 Mg/ml), Rs 132000 /bottle | ID: 21366458612
![KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014 - Medvitaz Pharma KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014 - Medvitaz Pharma](https://www.medvitaz.com/wp-content/uploads/2020/11/keytruda.jpg)
KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014 - Medvitaz Pharma
![KEYTRUDA® (pembrolizumab) has been registered for the treatment of patients with stage III melanoma — Melanoma NZ KEYTRUDA® (pembrolizumab) has been registered for the treatment of patients with stage III melanoma — Melanoma NZ](http://static1.squarespace.com/static/59cad46fc027d8327b7fea92/59cc06898a02c79aea602fa2/5d379beaf98fdc00012a75cc/1563942013531/Keytruda.jpg?format=1500w)